2023
Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand
Brooks J, Montgomery A, Dalbeth N, Sapsford M, Kee R, Cooper A, Quincey V, Bhana S, Gore-Massy M, Hausmann J, Liew J, Machado P, Sufka P, Sirotich E, Robinson P, Wallace Z, Yazdany J, Grainger R. Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand. The Lancet Regional Health - Western Pacific 2023, 38: 100843. PMID: 37520279, PMCID: PMC10372177, DOI: 10.1016/j.lanwpc.2023.100843.Peer-Reviewed Original ResearchInflammatory rheumatic diseasesSARS-CoV-2 infectionHospitalisation/deathOmicron variant infectionConnective tissue diseaseRheumatic diseasesVariant infectionCOVID-19SARS-CoV-2 Omicron variantSingle vaccine doseCOVID-19 hospitalisationMultivariable adjusted modelsCOVID-19 vaccination statusMultivariable logistic regressionCOVID-19 vaccinationHigh vaccination ratesRituximab useVaccine doseInflammatory arthritisVaccination statusClinical factorsTissue diseaseDisease characteristicsVaccination ratesRisk factors
2022
Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status
Maguire S, Al-Emadi S, Alba P, Aguiar M, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez K, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu T, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich D, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel N, Pera M, Pisoni C, Pons-Estel G, Quiambao A, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales R, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner M, Wise L, Worthing A, Zell J, Zepa J, Machado P, Yazdany J, Robinson P, Conway R. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status. Rheumatology 2022, 62: 1621-1626. PMID: 36124987, PMCID: PMC11181869, DOI: 10.1093/rheumatology/keac534.Peer-Reviewed Original ResearchConceptsObstetric outcomesPreterm birthVaccination statusPregnant womenUnvaccinated womenCOVID-19Exact testCOVID-19 vaccination statusCOVID-19 vaccine dosesCOVID-19 vaccinationCOVID-19 infectionFisher's exact testCOVID-19 diagnosisVaccine doseHospital admissionRheumatic diseasesMore dosesVaccine dosesPharmacological treatmentMusculoskeletal diseasesPregnancyDescriptive studyWomenOutcomesGreater numberBaseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Rider L, Parks C, Wilkerson J, Schiffenbauer A, Kwok R, Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche M, Levine M, Sattui S, Liew J, Harrison C, Moni T, Miller A, Putman M, Hausmann J, Simard J, Sparks J, Miller F, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh A, Duff E, Durrant K, Gheita T, Hill C, Howard R, Hoyer B, Hsieh E, Kibbi L, Kilian A, Kim A, Liew D, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee C, Singh J, Singh N, Ugarte-Gil M, Wallace J, Young K, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Foster G, Thabane L, Angevare S, Beesley R, Chock E, Degirmenci B, Felix C, Jin S, Mateus E, Peirce A, Sari E, Tseng R, Wang L, Zamora E. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 2022, 61: si143-si150. PMID: 35460240, PMCID: PMC9248066, DOI: 10.1093/rheumatology/keac249.Peer-Reviewed Original ResearchConceptsSystemic rheumatic diseasesCOVID-19 vaccinationRisk factorsDisease flareRheumatic diseasesHigher oddsSARS-CoV-2 severityFlare of diseaseIdiopathic inflammatory myopathiesSystemic lupus erythematosusOxford-AstraZeneca vaccineMultivariable logistic regressionHistory of reactionPotential risk factorsPfizer-BioNTech vaccineLarge international studyImmunosuppressive medicationsInternational studiesVaccines surveyAdverse eventsInflammatory myopathiesPolymyalgia rheumaticaProspective cohortPsoriatic arthritisBaseline factors
2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritis